Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure
25 juil. 2024 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
13 mars 2024 07h00 HE
|
BioCardia, Inc.
BioCardia & StemCardia biotechnology company partnership targets heart failure, the leading cause of death and a condition with limited treatment options
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
04 mars 2024 08h00 HE
|
BioCardia, Inc.
CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction...
BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs
06 sept. 2023 07h15 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial
05 sept. 2023 07h15 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results
09 août 2023 16h05 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023
02 août 2023 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected
24 juil. 2023 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease,...
BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan
08 juin 2023 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
International Collaborative Study Provides Insight into Gene Activation in One-Cell Embryos
28 déc. 2021 03h00 HE
|
Ovation Fertility
Nashville, Tenn., Dec. 28, 2021 (GLOBE NEWSWIRE) -- IVF services company Ovation Fertility announces the publication of a new collaborative study, “Human embryonic genome activation initiates at the...